Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Element Biosciences created a high-throughput benchtop device that can deliver a whole genome for $100 – half the price of ...

Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome solution and expanded clinical sequencing services, including supporting Florida State University’s new pediatric rare ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...

On July 31, 2025, the United States Department of Justice (DOJ) announced a $9.8 million settlement with Illumina, Inc. (Illumina) to resolve alleged False Claims Act (FCA) violations related to ...

SAN DIEGO, Feb. 3, 2026 — Illumina (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)’s Frozen Zoo®. The 50-year-old biobank is the world’s most ...

Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood ...

New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO ...